论文部分内容阅读
目的:观察促红细胞生成素与复方丹参滴丸合用对多发性骨髓瘤的贫血和高血黏的影响。方法:32例维持性血液透析患者随机分为两组,对照组14例行化疗及大剂量EPO治疗,治疗组18例在如上治疗基础上加用复方丹参滴丸,两组疗程16周。观察两组患者治疗前后血红蛋白(Hb)、红细胞比容(Hct)、红细胞计数(RBC)、血液流变学等指标的变化。结果:16周后,两组贫血明显改善,平均Hb、RBC无明显差异,但对照组治疗后Hct值高于治疗组(P<0.05);两组全血高切、低切黏度升高,治疗组升高幅度小于对照组(P<0.05)。结论:促红细胞生成素与复方丹参滴丸合用对多发性骨髓瘤患者的贫血及高血黏状态有良好的改善作用。
Objective: To observe the effect of combined use of erythropoietin and compound Danshen dripping pills on anemia and hyperviscosity in multiple myeloma. Methods: Thirty-two patients with maintenance hemodialysis were randomly divided into two groups. The control group received chemotherapy and high-dose EPO. In the treatment group, 18 cases received compound Danshen dripping pills on the basis of the above treatment. The two groups were treated for 16 weeks. The change of hemoglobin (Hb), hematocrit (Hct), red blood cell count (RBC) and hemorheology were observed before and after treatment in both groups. Results: After 16 weeks, the anemia in both groups improved obviously, while the average Hb and RBC showed no significant difference. However, the Hct value of the control group was higher than that of the treatment group (P <0.05) The treatment group increased less than the control group (P <0.05). Conclusion: Combination of erythropoietin and compound Danshen dripping pills can improve the anemia and hyperviscosity status of patients with multiple myeloma.